Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
3.520
-0.190 (-5.12%)
Nov 16, 2026, 4:00 PM EST - Market closed
← View all transcripts

3rd Annual Guggenheim Healthcare Innovation Conference

Nov 9, 2026

Summary

Phase II first-line pancreatic data showed 17.3-month median OS, favorable tolerability and weight stability; MAPKeeper-301 is enrolling ahead of schedule. A longer-follow-up update is guided for H1 2027, with phase III top-line data targeted for mid-2028.

Moderator

Next presenting company is Immuneering, and I am very pleased to welcome Ben Zeskind, PhD, CEO and Co-Founder of Immuneering. Ben, welcome.

Ben Zeskind
CEO and Co-Founder, Immuneering

Thanks for having me, Paul.

Moderator

All right. For those in the audience who might be newer to the story, could you quickly introduce the company and the idea behind the Deep Cyclic Inhibitor platform?

Ben Zeskind
CEO and Co-Founder, Immuneering

Sure, absolutely. Again, I am Ben Zeskind from Immuneering. Just to remind everyone, I will be making forward-looking statements today, so see our disclosures for more information, and thanks again to the Guggenheim team for having us. We started by asking a simple but profound question, and the question is, can you create a cancer treatment regimen that would have long survival, outstanding quality of life, and do it in all comers? I think the data, and we will talk more about the data today, the data from our phase II study shows that that is possible, right? I think that answers it with a resounding yes, right? We have 17.3 months median OS in first-line pancreatic cancer, with great tolerability and really strong weight stability and gain numbers.

The phase III that we have underway now, the MAPKeeper 301 study, that is going to be the definitive answer to the question. But why is this a profound question? It is a profound question because to date, there has really been a trade-off between how broadly a cancer drug works and how well tolerated it is. For instance, if you look at RAS inhibitors, we are not a RAS inhibitor, we are a MEK inhibitor, and we will talk about that. But if you look at RAS inhibitors, you can either go wide with a pan-RAS approach, but then you end up with some pretty gnarly side effects, or you can go narrow to a mutation-specific approach, like a G12D inhibitor, where you have fewer side effects, but it is a smaller population of patients that you target.

So there is this trade-off, broader population, more side effects, narrower population, fewer side effects. What we did with the Deep Cyclic Inhibition technology is we basically created a new technology that breaks that trade-off, that creates the potential that you can have your cake and eat it too. You can have an all-comers population in MAP kinase-driven cancers, like pancreatic cancer, and you can have outstanding tolerability. So that is really our our goal, and I think that is what the Deep Cyclic Inhibition technology is designed to do, is to provide long survival with outstanding quality of life in all comers. I think the data we have shared to date suggests that we are on track for that.

Moderator

Great. So maybe before getting into the really interesting data you had, just on the design of the molecule itself. So this is obviously targeting MEK, which is not the newest target, but how have you been able to achieve, I guess, your goals of the platform with the engineering behind this asset?

Ben Zeskind
CEO and Co-Founder, Immuneering

Yeah, it is a great question. This is not your grandfather's MEK inhibitor. So, MEK, just to remind everyone, MEK is in the same pathway as RAS, but it is downstream. So the pathway goes RAS, RAF, MEK, ERK. So, in theory, MEK has always been a really exciting target because it is sort of downstream at the narrow point of the funnel. It is hard to mutate around. That is why you almost never see a MEK mutant cancer. But the first-generation MEK inhibitors were really pretty disappointing, frankly. Even though they showed a substantial improvement in overall survival. So the COMBI-d study showed that adding a first-generation MEK inhibitor could extend survival. So they are validated clinically. MEK is a validated target clinically. MEK inhibitors are also validated commercially.

In 2025, there were over $3 billion in sales for MEK inhibitors in combination with RAF inhibitors, as well as monotherapy. MEK's a target that's validated clinically, and it's validated commercially. But the challenge with first-generation MEK inhibitors was that they were limited to a narrow population of patients, and they were poorly tolerated. On that trade-off that I talked about earlier between the breadth of the patients and the quality of life, they actually didn't do very well on either one. I think that's why MEK got a bad name. They were limited primarily to patients with BRAF mutant disease, and they had a lot of tolerability challenges with rashes and diarrhea, things kind of similar to what you see with pan-RAS inhibitors.

When you inhibit this pathway continuously, whether it's at RAS or MEK, you get a lot of the same toxicities. That was the first generation of MEK inhibitors. What happened was Neal Rosen at Sloan Kettering, in his lab, they figured out why the first-generation MEK inhibitors were only working in BRAF mutant disease. Based on their findings, scientists at Chugai were able to make a second-generation MEK inhibitor, which actually worked in RAS mutant disease as well as RAF mutant disease. That kind of expanded the population of patients that could potentially benefit, but it still had all the same tolerability challenges. I mean, we're talking about very high rates of rash and diarrhea and other side effects.

What we did with atebimetinib is we figured out how to engineer out, with the Deep Cyclic Inhibition, a lot of that toxicity, how to dramatically improve the tolerability, cut the rash rates to one-third of the original levels, engineer out two-thirds of the rate of rash, and so forth. That's really what makes atebimetinib unique as a third-generation MEK inhibitor, is that it's applicable to the broader set of patients, both BRAF and RAS mutant patients, but with tolerability that's really shown to be excellent in the trials that we've run so far. I think for anyone who's interested in understanding this trajectory, we actually just published a really nice paper in Cancer Research. It was actually featured on the cover of Cancer Research a couple weeks ago. I'd encourage everyone to check that out if they haven't seen the paper.

The journal also published a really nice spotlight commentary by independent investigators that I think really helps put this into context as a third-generation MEK inhibitor. The title of that spotlight was On the Quest for New Sources of Therapeutic Index. I think that's a good way to think about what we've been doing. We've been on a quest for new sources of therapeutic index, and I think the Deep Cyclic Inhibition technology enables that.

Moderator

Great. Thanks for that overview. Ben, you mentioned the clinical data you had earlier this year. Headline number, obviously, over 17 months survival. This is in frontline pancreatic cancer. I guess, what were the major takeaways from that update beyond the great survival number?

Ben Zeskind
CEO and Co-Founder, Immuneering

Yeah. This is data that we presented at ASCO this year. Dr. Peter Vu from UC San Diego presented it in an oral session at ASCO at the annual meeting. This is for 55 first-line pancreatic cancer patients treated with atebimetinib in combination with chemo. As you pointed out, 17.3 months median overall survival we reported there, which is among the highest median overall survival numbers that we are aware of in any phase II and first-line pancreatic cancer. Importantly, I know there is a lot of excitement around RAS inhibitors. No RAS inhibitor has shown a median OS as high as 17.3 months in any setting in pancreatic cancer. Let me repeat that. No RAS inhibitor has shown a median OS as high as 17.3 months in any setting in pancreatic cancer. That is really important.

Let us get back to our goals that I mentioned at the beginning, right? We wanted to achieve long survival with outstanding quality of life in all comers. I think what was equally important about the data that we shared at ASCO was the tolerability. We only saw two categories of treatment-related adverse events at the grade three level in more than 10% of patients, and they were both associated with the chemotherapy that we were combining with. No categories of grade three adverse events at more than 10% of patients that were attributed to atebimetinib. I think that tolerability is really exciting, and it certainly compares favorably to what RAS inhibitors have shown in a similar setting, which is six categories of treatment-related adverse events at the grade three level in more than 10% of patients.

Again, we are at sort of one-third the level that you would expect from continuous inhibition of a pathway. The other thing that was really exciting that we reported is 84% of evaluable patients were weight stable or gaining weight at three months. That is really important because when cancer patients lose weight, it is not just that they lost their appetite or it is a side effect of the chemo. This is a particular and very insidious attribute of many tumors where they actually secrete soluble factors which break down the patient's muscle and fat tissue. It is a phenomenon called cachexia. It is a major contributor to the risk of death in cancer patients. In fact, there was recently a great study out of Sloan Kettering. Ed Reznik's lab led it. Wungki Park was on it as well.

They looked across all cancers, and they showed that when patients have this cachectic weight loss, the hazard ratio is three relative to patients that don't. Three. That means patients who have this cachectic weight loss have triple the risk of death. This is a critically important phenomenon to attack in order to drive long survival, and it's essentially an independent mechanism of shrinking tumors. We designed atebimetinib to do both, to shrink the tumors and to counteract this cachexia. As far back as 2018, we've been talking about this as one of the design goals.

The fact that we see 84% of evaluable patients weight stable or gaining weight at three months, I think is great from a contribution to overall survival, and it's also great for quality of life because that means patients, they have their strength, their stamina, they're well-appearing, and I think all these things really contribute to the goal of outstanding quality of life. To sum up our ASCO data, I think it's consistent with our goals of driving long survival, outstanding quality of life, and really doing it in all comers because I should emphasize that the phase II, as the phase III does, requires no genetic testing in advance. We don't care if it's KRAS G12D, G12V, G12R, Q61H, RAS unknown. No genetic testing is required, and I think that breadth, that all comers criteria for enrollment in the trial is really important as well.

Moderator

Maybe just following up, is the avoidance of the cachexia like an on-mechanism factor for MEK inhibition or something specific to the molecule itself?

Ben Zeskind
CEO and Co-Founder, Immuneering

No, it's a characteristic of MEK as a class, but the Deep Cyclic Inhibition we designed to enhance that, to essentially do more of it. But yeah, there's some prior literature on MEK inhibitors having an anti-cachectic effect. What we presented as far back as 2018 at AACR was that by optimizing the pharmacokinetics, we believed you could enhance the anti-cachectic effect. What we presented at the AACR Pancreatic Cancer Conference just a few months ago in September was essentially to compare the number of valuable patients on our study who are weight stable or gaining weight to a benchmark in pancreatic cancer, and we found that we had about twice as many patients who are weight stable or gaining weight as you would expect based on that benchmark in pancreatic cancer.

We also show that the patients who are weight stable or gaining weight have significantly longer survival than the ones that lose weight. In fact, using that same data cutoff we used for ASCO of late April, the patients who are weight stable or gain weight actually had median not yet reached for their overall survival in the data we presented at AACR Pancreatic Cancer.

Moderator

Speaking of that follow-up, you've sort of extended the follow-up of the study because patients are living longer than you had perhaps projected. What would be the next expected readout for this study, and what should we look for in that update?

Ben Zeskind
CEO and Co-Founder, Immuneering

Yeah, it's a great question, Paul. Exactly as you said, the study that we presented at ASCO, we've recently said that we've extended that because patients are living longer on atebimetinib than projected, and we've guided to sharing an update in the first half of 2027. That'll be coming in the first half of next year, and it's essentially substantially longer follow-up, right? The median follow-up time as of the data cutoff we presented at ASCO was 11.6 months in the 55 patients, and so I think it's safe to assume that in data presented in the first half of 2027, there'll be substantially longer follow-up. Look, we believe this is important because longer follow-up really speaks to the tail of the survival curve. It really speaks to how that changes as it matures, and with some treatments, that goes in the other direction, right?

Even with pan-RAS inhibitors, right? I mean, I think we saw daraxonrasib presented over 13 months median overall survival at ASCO, and then in the recent FDA update, with a newer data cutoff, it had gone down to 12.4 months. So that can happen, and certainly though, with a drug like atebimetinib that's really designed for durability, right? I mean, when you have this outstanding quality of life where patients are able to sort of maintain their strength, their stamina, with the anti-cachectic effect, all these things were designed for durability. They were designed to really shine over time, and similarly, to have this all-comers attribute where it's not specific to any one particular KRAS mutation, that makes it harder for the tumor to get around it, right? That makes it harder for acquired alterations to get around it.

All these factors, certainly we designed atebimetinib to really have durability, so I think that update in the first half of 2027 is really going to be informative for the question of durability.

Moderator

Okay, great. You also referred to the phase III, MAPKeeper-301, that is enrolling right now. Can you walk us through the trial design, the dosing schedule with the chemo, and how the enrollment is progressing?

Ben Zeskind
CEO and Co-Founder, Immuneering

Yeah, absolutely. That is right. This is our phase III, MAPKeeper-301, and this is in first-line pancreatic cancer. We are testing the same combination that we reported at ASCO from the phase II, atebimetinib in combination with gemcitabine and nab-paclitaxel given every other week. Pretty straightforward design, overall survival as the primary endpoint. Randomized study against standard of care, gemcitabine and nab-paclitaxel chemo. We are really excited about this study because enthusiasm has been high. It is enrolling ahead of schedule, and I think a big part of that is the data that we shared at ASCO, right? 17.3 months median OS is really exciting, and I think that has driven it, certainly the outstanding quality of life that we reported at ASCO.

Both the numbers that I talked about with the limited categories of treatment-related adverse events at the grade three level in more than 10% of patients, the weight stability, but also just qualitatively, right? At ASCO, Dr. Vu, who presented the data, was asked how the patients were doing, and he is quoted in OncLive as saying, In my experience treating a lot of patients on this study, patients have done incredibly well from a quality of life perspective. It has been remarkable to see. I think that kind of experience certainly makes it a trial that is generating a lot of excitement. We are honored to have Eileen O'Reilly from Sloan Kettering as the lead PI for the study. I think all that is really exciting.

We recently announced we're ahead of schedule with enrollment, and we've guided to top-line readout in mid-2028 with the potential to accelerate that. Things are just moving really fast, and it's a very exciting time.

Moderator

What kind of factors might pull that timeline in to be sooner rather than later?

Ben Zeskind
CEO and Co-Founder, Immuneering

I think just continued rapid enrollment. The excitement is good. We have 76 sites already listed on clinicaltrials.gov. We update that regularly. We're just starting to get European sites up and running. I think the demand that we're seeing is just really robust. We're honored. Every one of those sites represents a great investigator who's looked at the data and sees this as an important option to have available for their patients to participate in. We have great partners, great investigators, and just really moving at a rapid pace.

Moderator

How do you think about working around or perhaps fitting in with the emergence of the pan-RAS inhibitor sort of strategy, now approved in second line, but also very active to move into earlier lines? How does that sort of fit in with your strategy?

Ben Zeskind
CEO and Co-Founder, Immuneering

Yeah. Well, I think it's important to point out that we have the best overall data in first line, right? So 17.3 months median OS, only two categories of treatment-related adverse events at the grade three level in more than 10% of patients, and 84% of evaluable patients weight stable or gaining weight at three months. We believe that represents the most attractive phase II data out there for first-line pancreatic cancer. That said, it's great that there are emerging options available in the second-line setting. I think ultimately, one scenario that could be really beneficial for patients would be atebimetinib plus Gem Nab in the first line, followed by a pan-RAS inhibitor in the second line. One of the nice things about atebi is we don't drive the kind of resistance that would prevent someone from getting that in the second line, right?

If you look at the data we reported in April at AACR on acquired alterations, we very rarely see acquired alterations in RAS or in the MAP kinase pathway more generally in patients treated with atebimetinib. Whereas, the acquired alterations that are most commonly associated with resistance to daraxonrasib are KRAS amplifications or BRAF mutations. There's been some good publications on that. So we're not driving the kind of acquired alterations that would likely be associated with resistance to daraxonrasib. It's just a different mechanism. We think it's ultimately going to be good for patients to alternate, right, between a non-RAS, a RAS, a non-RAS, a RAS, and basically keep the tumor off balance, right? Require the tumor to keep changing to try to get around it.

But certainly, I think based on the data to date, having atebi plus Gem Nab in the first line, we believe is going to be a really compelling option.

Moderator

Great. Yeah, obviously the phase III is combining with Gem Nab. You also have an earlier phase arm combining atebi with FOLFIRINOX. How does that sort of work into your strategy?

Ben Zeskind
CEO and Co-Founder, Immuneering

Yeah. I'm so glad you asked that. We absolutely do another phase II arm in combination with FOLFIRINOX. So far, we've shared from that just a case study, but a really exciting one of a patient with a complete response, which is always really exciting in pancreatic cancer. We see those data, it's open label, so we see those data and we're thinking hard about if and when to share them. Stay tuned.

Moderator

Great. Beyond, I guess, pancreatic cancer, you're also expanding into other indications, including lung cancer. What's the rationale there? What are the combos that you're looking into, and what do you want to see when you update data next year?

Ben Zeskind
CEO and Co-Founder, Immuneering

Yeah, absolutely. The MAP kinase pathway drives a large percentage of all cancers, right? It's not specific to pancreatic cancer. We're really excited to take it next into lung cancer, right? This is a study in combination with Regeneron's anti-PD-1, cemiplimab. We've guided to dosing the first patient by the end of this year, and as you said, sharing initial data by the end of next year. The preclinical data for this combination is really compelling, both our data and data from others. Let's start with others. Jedd Wolchok's lab has published data showing that a pulsatile MEK inhibition, not specific to ours, but just in general, pulsatile MEK inhibition enhances the activity of immunotherapy.

Consistent with that external work, we actually presented just this past Friday at SITC two animal models, both showing really exciting results when we combine atebimetinib with an anti-PD-1. In a colorectal cancer model, we saw about half the mice essentially cured, durable, complete regressions that lasted even beyond stopping treatment. In a lung model, a tougher sort of cold tumor model, we still saw a 1.8-fold increase in survival when we added atebimetinib in combination with the PD-1. Just really compelling preclinical data, and we're excited to start evaluating that in patients.

Moderator

Great. Then maybe with the last couple minutes, beyond atebi, you also have an earlier pipeline that is moving towards the clinic perhaps. How do you think about the platform in general beyond atebi?

Ben Zeskind
CEO and Co-Founder, Immuneering

Yeah, I mean, it goes back to the title of that spotlight, On the Quest for New Sources of Therapeutic Index, right? I mean, our goal is to help cancer patients have long survival with outstanding quality of life in all comers, right? So we want to expand even beyond the MAP kinase pathway, right, to other pathways in cancer and other targets where we can take this same Deep Cyclic Inhibitor technology and again, break the trade-off, right? So rather than having to choose between a broader population but more side effects or a narrower population and fewer side effects, have your cake and eat it too, right? Make drugs that can have outstanding quality of life and do so in broad populations in cancer. The Deep Cyclic Inhibition technology, nothing about it is specific to MEK as a target, right?

That does not mean it will work for every target. It will not. But there is a lot of other targets and pathways in oncology that we believe it is well-suited for. So, we have a very active preclinical pipeline where we are applying this Deep Cyclic Inhibitor technology to other targets and pathways, and we think that is just going to help us reach more patients. All comers is kind of a philosophy, not just an enrollment criteria. Help us reach all comers in cancer with outstanding quality of life and long survival.

Moderator

Great. So maybe we can close by reminding us of your cash runway and your upcoming catalysts for the next 12 months.

Ben Zeskind
CEO and Co-Founder, Immuneering

Yeah. Well, I think it's going to be an exciting time, right? We have the first patient dosed in the lung study. We have guided to that by the end of the year. First half of next year, we have guided to an update on the data we shared at ASCO, the phase II data in first-line pancreatic cancer in combination with gemcitabine and nab-paclitaxel. By the end of next year, initial data from the lung study in combination with the anti-PD-1. Then the top-line readout from the phase III in mid-2028. Really exciting and steady stream of updates there. We have guided to cash runway into the fourth quarter of 2028, so well beyond that top-line readout.

Moderator

Okay, fantastic. I think we will wrap it there. Thanks so much, Ben, for joining us.

Ben Zeskind
CEO and Co-Founder, Immuneering

Thank you, Paul, for having me, and thanks everyone for listening.